Thelimited efficacy of conventional drugs and an increase in theiradverse effects have created the need for the identification ofalternative therapeutic agents. The efficacy of the biological agentsin the treatment of different diseases has become a field of interestfor many researchers. Although research on many agents has notreached the clinical testing phase, there are several biologicalagents that have been approved due to their ability to targetspecific immunological pathways.
Golimumabis a biological agent that is produced from monoclonal antibody. Theagent is used in the treatment of rheumatoid arthritis and ankylosingspondylitis (Park & Jeen, 2015). Golimumab is an anti-TNF IgGmonoclonal antibody that has an affinity for trans-membrane andsoluble TNF. It works by targeting and neutralizing factors thatcontribute towards the inflammation. The drug was discovered byJanssen Biotech, Inc. This technology will be presented in the 16thMediterranean Congress of Rheumatology that will be held on September1, 2016, in Sarajeve, Bosnia (Conference Website, 2016).
Vedolizumabis a biological agent that was discovered by MillenniumPharmaceutical, Inc. The drug is used to treat Crohn’s disease andulcerative colitis (Amiot & Peyrin-Biorulet, 2015). The drugconsists of anti-tumor necrosis factor, adalimumab,therapies-infliximab, and golimumab. These components help the drugfunction by delivering an anticytokine action (Schreiber, 2014).However, the drug is not effective in all cases of Crohn’s diseaseand ulcerative colitis. This technology will be presented in theInflammatory Bowel Disease Conference that will be held in Boston, MAin September 9, 2016 (Conference Website, 2016).
Natalizumabis an anti-adhesion drug that is classified as an IgG4 monoclonalantibody. This drug was developed by Biogen Idec and sold in acommercial name, Tysabri (Amiot & Peyrin-Biorulet, 2015). Thedrug is used in the treatment of Crohn’s disease and multiplesclerosis. It is administered through intravenous in 28 days.Natalizumab is an integrin receptor antagonist that works by blockingalpha-4 integrin, which interferes with α4β7 in the adhesionmolecule of the cell. This prevents inflammatory immune cells fromattaching to the cells in the lining of blood brain barrier andintestine. This technology will be presented in the ClinicalGastroenterology and Hepatology Conference, which will be held onOctober 3-5, 2016 in Toronto Canada (Conferenceseries, LLC, 2016).
Tofacitinibis a drug that is put in the class of Janus kinase inhibitors. Themain players in the discovery of the drug are Pfizer and the NationalInstitute of Health (Park & Jeen, 2015). Tofacitinib is mainlyused in the treatment of rheumatoid arthritis, inflammatory boweldisease, and psoriasis. Tofacitinib works by inhibiting JKA2, JAK1,and JAK 3, which results in the modulation of signals of IL-2, 4, 7,15, and 21. This results in the blockage of some functions ofpro-inflammatory cytokines, which in turn controls inflammation. Thistechnology will be presented in the Inflammatory Bowel DiseaseConference. The conference will be held in Boston, MA in September 9,2016 (Conference Website, 2016).
Differentbiological agents are preferred because they have fewer side effects.In addition, these therapeutic agents help the health careprofessionals target specific immunological pathways, which enhancestheir efficacy compared to conventional drugs. Most importantly, oneagent can be used to treat more than one medical condition. Forexample, Vedolizumab can be used to treat Crohn’s disease andulcerative colitis, while the health care providers can useNatalizumab to cure Crohn’s disease and multiple sclerosis.Therefore, biological agents give the hope of the discovery of saferand more effective drugs.
Amiot,A. & Peyrin-Biorulet, L. (2015). Current, new and futurebiological agents on the horizontal for the treatment of inflammatorybowel diseases. TherapeuticAdvances n Gastroenterology,8 (2), 66-82.
Conferenceseries,LLC (2016). Clinical gastroenterology and hepatology.Conferenceseries,LLC.Retrieved June 27, 2016, fromhttp://clinicalgastroenterology.conferenceseries.com/
Park,S. & Jeen, Y. (2015). Current and emerging biologics forulcerates. Archiveof Gut and Liver,9 (1), 18-27.
Schreiber,S. (2014). Commentary: Vedolizumab: A new mechanism of action for thetreatment of ulcerative colitis. GastroenterologyHepatol,10 (1), 67-68.
TheConference Website (2016). Rheumatoid conferences in 2016 (21conferences). TheConference Website.Retrieved June 27, 2016, fromhttp://www.medical.theconferencewebsite.com/conferences/rheumatology
TheConference Website (2016). Gastroenterology conferences in 2016 (58conferences). ConferenceWebsite.Retrieved June 27, 2016, fromhttp://www.medical.theconferencewebsite.com/conferences/gastroenterology